1. Home
  2. DMLP vs RARE Comparison

DMLP vs RARE Comparison

Compare DMLP & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DMLP

Dorchester Minerals L.P.

N/A

Current Price

$28.48

Market Cap

1.5B

Sector

Energy

ML Signal

N/A

Logo Ultragenyx Pharmaceutical Inc.

RARE

Ultragenyx Pharmaceutical Inc.

N/A

Current Price

$16.03

Market Cap

1.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DMLP
RARE
Founded
2003
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.6B
IPO Year
2002
2013

Fundamental Metrics

Financial Performance
Metric
DMLP
RARE
Price
$28.48
$16.03
Analyst Decision
Buy
Analyst Count
0
21
Target Price
N/A
★ $25.35
AVG Volume (30 Days)
105.5K
★ 3.3M
Earning Date
11-05-2026
11-03-2026
Dividend Yield
★ 9.81%
N/A
EPS Growth
N/A
★ 7.31
EPS
★ 1.75
N/A
Revenue
$152,832,000.00
★ $673,000,000.00
Revenue This Year
N/A
$12.70
Revenue Next Year
N/A
$29.06
P/E Ratio
$16.27
★ N/A
Revenue Growth
N/A
★ 20.13
52 Week Low
$20.85
$12.73
52 Week High
$31.08
$39.89

Technical Indicators

Market Signals
Indicator
DMLP
RARE
Relative Strength Index (RSI) 46.47 49.08
Support Level $27.90 $14.11
Resistance Level $29.26 $17.67
Average True Range (ATR) 0.81 0.90
MACD -0.10 0.03
Stochastic Oscillator 37.97 37.06

Price Performance

Historical Comparison
DMLP
RARE

About DMLP Dorchester Minerals L.P.

Dorchester Minerals LP operates as the owner of producing and non-producing crude oil and natural gas mineral, royalty, overriding royalty, net profits, and leasehold interests. The company generates revenues from royalties, net profits interests, lease bonuses, and others.

About RARE Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.

Share on Social Networks: